[Field Pattern] "Can We Skip 'Pre-Seed' in Deep Tech?"
What founder psychology reveals: Are we legitimate enough to ask for that much money?
Capital stages feel like developmental milestones. In science ventures, they are not.
During early-stage mentoring and coaching sessions with science founders, this confusion keeps resurfacing because the startup hype narrative is counterintuitive – but the system misses it and founders ‘feel’ it.
They are often times just exiting a substantial university grant funding, moving on to the next stage of their venture building. Prototypes exist. Internal validation is underway. The next real inflection point will require several million more.
Their question was simple:
Are we still pre-seed?
Is it allowed to skip straight to seed? (like there was a law against that - this is how founders are trained…)
It sounds procedural. It is not.
The Visible Problem
On the surface, the confusion seems rational.
They received public funding. Now they consider venture capital. Venture capital operates with stages. Pre-seed, seed, Series A... Each stage implies ticket size. Each ticket size implies valuation. Each valuation implies maturity.
So the team tries to locate itself on that ladder.
If they are pre-seed, the ticket will be small.
If they are seed, the ticket can be larger.
If they skip pre-seed, perhaps they can justify the amount they actually need.
The categories feel like gates.
They assume they must pass through them in order.
That assumption feels natural.
It is also structurally wrong.
Structural Reframing
There is no scientific boundary between pre-seed and seed (or any other stages).
There is no validation threshold that marks the transition.
No regulatory gate.
No industrial inflection point.
Stage labels were designed for revenue-compressible uncertainty.
Science does not give that.
Uncertainty collapses through evidence, replication, industrial stress testing, and regulatory exposure. That collapse has nothing to do with whether a fund calls its check pre-seed or seed.
In most European funds, the label does not even originate from your technology. It originates from fund structure.
Fund size determines portfolio allocation.
Portfolio allocation determines initial ticket range.
Ticket range implies valuation band.
Valuation band gets labeled.
The label is portfolio math.
It is barely a measurement of your scientific state.
When founders ask whether they can “skip pre-seed,” they assume there exists a developmental rung on the ladder they must climb.
There is not.
There is only a capital requirement defined by the cost of your next real uncertainty reduction.
Everything else is taxonomy.
Collapse Path
The damage does not happen immediately.
It begins when capital is sized to fit a label rather than to fit the physics of the venture.
A team that needs €5M to reach external validation raises €800k because that is “pre-seed appropriate.”
€800k extends runway by 9 months → External validation requires 18 months → The dominant uncertainty remains intact → Valuation increases artificially → Next round becomes structurally harder.
The company appears to have advanced a stage. It gets celebrated for shallow metrics like “closed follow-on funding”, still years away from industrial deployment. Internally, it slowly dies.
The inverse collapse is subtler.
A team avoids raising a substantial round because they believe they must first “earn” seed through smaller tickets. Experiments stretch. Industrial validation slows. The capital density never matches the uncertainty density.
In both cases, the same structural error sits underneath:
Stage mythology replaced capital geometry.
The question was never whether pre-seed can be skipped.
The real question is whether the capital instrument you are about to introduce can materially collapse the uncertainty that actually governs your venture.
And that is not a stage question.
To see the underlying question, the decision logic and the answer, next we need to separate three dimensions that founders are routinely trained to compress into one:
If you are building for or withing a science venture and want to stop sizing capital according to stage mythology, the next section breaks down the capital geometry model:
– how to map dominant uncertainty
– how to calculate capital density
– how to align instrument clock speed
– how to choose trajectory type
Upgrade below and ask your strategic question for the next edition: